Technical Analysis for FPRX - Five Prime Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 9.05 2.72% 0.24
FPRX closed up 2.72 percent on Friday, May 24, 2019, on 84 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical FPRX trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 2.72%
Oversold Stochastic Weakness 2.72%
180 Bearish Setup Bearish Swing Setup 2.14%
Wide Bands Range Expansion 2.14%
Oversold Stochastic Weakness 2.14%
Slingshot Bearish Bearish Swing Setup -3.42%

Older signals for FPRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company's product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.
Biotechnology Cancer Life Sciences Solid Tumors Monoclonal Antibodies Tyrosine Kinase Receptors Pfizer Gastric Cancer Glaxosmithkline Inflammatory Disease
Is FPRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 18.57
52 Week Low 7.84
Average Volume 260,007
200-Day Moving Average 12.0125
50-Day Moving Average 11.7394
20-Day Moving Average 10.0825
10-Day Moving Average 9.111
Average True Range 0.5468
ADX 26.8
+DI 20.2302
-DI 29.4314
Chandelier Exit (Long, 3 ATRs ) 10.5896
Chandelier Exit (Short, 3 ATRs ) 10.170399999999999
Upper Bollinger Band 12.2062
Lower Bollinger Band 7.9588
Percent B (%b) 0.26
BandWidth 42.126457
MACD Line -0.8289
MACD Signal Line -0.7793
MACD Histogram -0.0496
Fundamentals Value
Market Cap 254.12 Million
Num Shares 28.1 Million
EPS -4.26
Price-to-Earnings (P/E) Ratio -2.12
Price-to-Sales 37.28
Price-to-Book 3.79
PEG Ratio 0.14
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.44
Resistance 3 (R3) 9.42 9.27 9.38
Resistance 2 (R2) 9.27 9.17 9.28 9.35
Resistance 1 (R1) 9.16 9.11 9.22 9.18 9.33
Pivot Point 9.01 9.01 9.04 9.02 9.01
Support 1 (S1) 8.90 8.91 8.96 8.92 8.77
Support 2 (S2) 8.75 8.85 8.76 8.75
Support 3 (S3) 8.64 8.75 8.73
Support 4 (S4) 8.66